2026-03-11T22:51:35Z https://repository.lib.tottori-u.ac.jp/oai

oai:repository.lib.tottori-u.ac.jp:00004762 2023-09-28T23:54:22Z 1:9 2:12 23:34:993:994

Turning Point in the Treatment of Mantle Cell Lymphoma 00192823 Motokura, Toru モトクラ, トオル Motokura, Toru Yonago Acta medica　編集委員会 bendamustine bortezomib ibrutinib bendamustine bortezomib ibrutinib Mantle cell lymphoma (MCL) is an incurable type of B-cell lymphoma. It is typically composed of small-to-medium-sized cleaved lymphoid cells with cyclin D1 protein expression due to the chromosomal translocation t(11;14)(q13;q32). Even with the development of rituximab, an anti-CD20 antibody drug, the long-term outcome of patients with MCL has not improved. Recently, new agents have been used in clinical settings, and the outcome of patients with MCL is expected to improve. The treatment of MCL may be at a turning point from intensive chemotherapy to chemotherapy-free treatment. In this study, a recent progress in the diagnosis and treatment of MCL is reviewed. Tottori University Medical Press 2019-03-28 eng journal article VoR https://repository.lib.tottori-u.ac.jp/records/4762 10.33160/yam.2019.03.001 Yonago Acta Medica. 2019, 62(1), 1-7 https://www.jstage.jst.go.jp/article/yam/62/1/62_2019.03.001/_article/-char/en https://www.jstage.jst.go.jp/article/yam/62/1/62_2019.03.001/_article/-char/en http://www.lib.tottori-u.ac.jp/yam/yam/yam62-1/62-1contents.html http://www.lib.tottori-u.ac.jp/yam/yam/yam62-1/62-1contents.html AA00892882 05135710 Yonago Acta Medica Yonago Acta Medica 62 1 1 7 https://repository.lib.tottori-u.ac.jp/record/4762/files/yam62(1)_1.pdf application/pdf 856.5 kB 2023-03-15